Regeneron Pharmaceuticals (NQ:REGN)

These stocks are still relatively cheap, but don't expect them to stay that way for long.

Topics Artificial Intelligence

3 Stocks to Buy Before 2024 That Can Set You Up For Life ↗

December 14, 2023

Via The Motley Fool

Reasonable growth and debt and a high ROIC for REGENERON PHARMACEUTICALS (NASDAQ:REGN). ↗

December 14, 2023

Exploring REGENERON PHARMACEUTICALS (NASDAQ:REGN)'s quality characteristics.

Via Chartmill

3 Gene-Editing Stocks With the Potential to Mint Millionaires ↗

December 13, 2023

Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.

The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally.

Biotech Is Coming Back, Can The Run Last? ↗

December 11, 2023

Via Talk Markets

(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest ↗

December 11, 2023

Via Benzinga

11 Analysts Have This to Say About Regeneron Pharmaceuticals ↗

November 28, 2023

Via Benzinga

If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today ↗

November 17, 2023

Via Benzinga

Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year

December 11, 2023

Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes

December 10, 2023

Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes

December 10, 2023

If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.

How Is The Market Feeling About Regeneron Pharmaceuticals? ↗

November 16, 2023

Via Benzinga

Where Regeneron Pharmaceuticals Stands With Analysts ↗

November 09, 2023

Via Benzinga

3 biotech powerhouses poised to thrive amid sector rebound

December 08, 2023

Via MarketBeat

Topics ETFs

Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire? ↗

December 08, 2023

Regeneron has been an excellent investment in recent years. Can that trend continue?

Via The Motley Fool

Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

December 07, 2023

Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO

December 07, 2023

Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise ↗

December 06, 2023

Via Investor's Business Daily

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗

December 04, 2023

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

Via The Motley Fool

GOOG Stock Alert: Alphabet Is Spending Money in All the Wrong Places ↗

December 02, 2023

The company continues to buy back Alphabet stock in large quantities. As for its other equity investments, it ought to stick with the S&P 500.

$1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

Topics Stocks

December 01, 2023

Via Benzinga

Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio

November 30, 2023

We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January.

Biotech And Healthcare Portfolio Playbook For December 2023/24 ↗

November 27, 2023

Via Talk Markets

Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales ↗

November 27, 2023

Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation.

Via Investor's Business Daily

Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder ↗

November 27, 2023

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that...

Via Benzinga

Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease

November 27, 2023

9 Health Care Stocks With Whale Alerts In Today's Session ↗

November 16, 2023

Via Benzinga

Regeneron Announces Investor Conference Presentation

November 15, 2023

Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)

November 13, 2023

With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.

7 Underappreciated Biotech Stocks to Pick Up on the Cheap ↗

November 09, 2023